Further advances revealed promising TGF-β’s downstream targets or modulators of signaling (e.g., Smad7, Smad3-dependent noncoding RNA) to therapeutically target CKD [35,36,37]; however, none has emerged so far in the clinic. This evidence concerns the gene SMAD7 and chronic kidney disease.